ArticleBMC medical informatics and decision making2025
Unlocking the link: predicting cardiovascular disease risk with a focus on airflow obstruction using machine learning.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of a machine learning-based prediction model for prolonged length of stay after laparoscopic gastrointestinal surgery: a secondary analysis of the FDP-PONV trial.BMC gastroenterology · 2025Trial
- Identification of cardiovascular disease in patients with kidney stone disease using explainable machine learning.Frontiers in cardiovascular medicine · 2026Article
- COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRespiratory diseases and Cardiovascular Diseases (CVD) often coexist, with airflow obstruction (AO) severity closely linked to CVD incidence and mortality. As both conditions rise, early identification and intervention in risk populations are crucial. However, current CVD risk models inadequately consider AO as an independent risk factor. Therefore, developing an accurate risk prediction model can help identify and intervene early.
methodsThis study used the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and NHANES 2007-2012 datasets. Inclusion criteria were participants aged over 40 with complete AO and CVD data; exclusions were those with missing key data. Analysis included 12 variables: age, gender, race, PIR, education, smoking, alcohol, BMI, hyperlipidemia, hypertension, diabetes, and AO. Logistic regression analyzed the association between AO and CVD, with sensitivity and subgroup analyses. Six ML models predicted CVD risk for the general population, using AO as a predictor. RandomizedSearchCV with 5-fold cross-validation was used for hyperparameter optimization. Models were evaluated by AUC, accuracy, precision, recall, F1 score, and Brier score, with the SHapley Additive exPlanations (SHAP) enhancing explainability. A separate ML model was built for the subpopulation with AO, evaluated similarly.
resultsThe cross-sectional analysis showed that there was a significant positive correlation between AO occurrence and CVD prevalence, indicating that AO is an important risk factor for CVD (all P < 0.05). For the general population, the XGBoost model was selected as the optimal model for predicting CVD risk (AUC = 0.7508, AP = 0.3186). The top three features in terms of importance were age, hypertension, and PIR. For the subpopulation with airflow obstruction, the XGBoost model was also selected as the optimal model for predicting CVD risk (AUC = 0.6645, AP = 0.3545). SHAP shows that education level has the greatest impact on predicting CVD risk, followed by gender and race.
conclusionAO correlates positively with CVD. Age, hypertension, PIR affect CVD risk most in general. For AO patients, education, gender, ethnicity are key CVD risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.